Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
|Videos|May 20, 2021
The Importance of the Lengthening the Patient Lifecycle
Pharmacy Times spoke with Lauren Simko, managing performance specialist at Pharmacy Development Services, about her presentation "Elevated Patients Experiences: Lengthen the Patient Lifecycle to Increase Revenue."
Advertisement
Pharmacy Times spoke with Lauren Simko, managing performance specialist at Pharmacy Development Services, about her presentation "Elevated Patients Experiences: Lengthen the Patient Lifecycle to Increase Revenue."
Simko explained how lengthening the patient lifecycle is important for the overall development of pharmacies and pharmacists' performance.
Advertisement
Related to this article
A phase 3 trial shows etentamig boosts response and delays progression in triple-class exposed RRMM.
IRAKLIA data show that isatuximab OBI boosts comfort and satisfaction vs IV in multiple myeloma, enabling fast at-home dosing with strong completion rates.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Long-term CASSIOPEIA Registry results show that daratumumab maintenance supports sustained minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma.
A phase 1/2 analysis found rapid, deep responses with mezigdomide plus elranatamab in patients with relapsed or refractory multiple myeloma, but the small cohort and limited follow-up require cautious interpretation.
Hemoglobin, platelets, bleeding, pericardial effusions, and intrapulmonary shunting top the monitoring list for patients with pulmonary arterial hypertension (PAH) starting with sotatercept, according to Vallerie McLaughlin, MD.
Marie-Claire Seeley, RN, MNurs, PhD, discusses standing tests, medication review, and what inflammatory findings may mean for future POTS treatment.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Tavapadon, First D1/D5 Agonist for Parkinson Disease
2
Pharmacists Can Close CKD Medication Adherence Gaps, PHTI Says
3
CagriSema Tops Tirzepatide 5 mg for Weight Loss in REIMAGINE 5
4
FDA Approves Tiratricol, First Treatment for MCT8 Deficiency
5